Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2022

View Archived Issues

Targeting NMNAT2 confers neuroprotection in glaucoma

Hangzhou Zhongmei Huadong Pharmaceutical divulges GLP-1 receptor agonists

Universite du Luxembourg discloses new PDE6D inhibitors

Ranok Therapeutics presents new CHAMPs for cancer

Beijing Jacobio Pharmaceuticals identifies new glutaminase inhibitors

Shanghai De Novo Pharmatech synthesizes new ATR kinase inhibitors

Discovery of potent and orally bioavailable CSNK1A1 inhibitors

Clec9A-M2e construct may be a step towards a universal influenza vaccine

ANGPTL7 as a novel therapeutic target for glaucoma

TBK1 inhibition is neuroprotective in optic neuropathies

iBio presents preclinical data on monoclonal antibody candidate IBIO-101 for solid tumors

Ichnos selects trispecific antibody ISB-2001 for development in multiple myeloma

Aqilion advances program for chronic inflammatory bowel disease

Researchers develop a murine model of TEK Schlemm's canal conditional knockdown glaucoma

Comparative study focuses lens of human reproductive aging

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...